

47. (Amended) A composition containing an anti-human CD23 antibody according to claim 44 and a pharmaceutically acceptable carrier.

49. (Amended) A chimeric anti-human CD23 antibody wherein the variable light domain comprises the polypeptide encoded by SEQ ID NO: 3 and the variable heavy domain comprises the polypeptide encoded by SEQ ID NO: 4 with the exception that the asparagine codon at position 75 is replaced with a lysine.

54. (Amended) A composition comprising an anti-human CD23 antibody according to claim 48 and a pharmaceutically acceptable carrier.

55. (Amended) A composition comprising an anti-human CD23 antibody according to claim 49 and a pharmaceutically acceptable carrier.

56. (Amended) A composition comprising an anti-human CD23 antibody according to claim 50 and a pharmaceutically acceptable carrier.

57. (Amended) A composition comprising an anti-human CD23 antibody according to claim 51 and a pharmaceutically acceptable carrier.

58. (Amended) A composition comprising an anti-human CD23 antibody according to claim 52 and a pharmaceutically acceptable carrier.

59. (Amended) A composition comprising an anti-human CD23 antibody according to claim 53 and a pharmaceutically acceptable carrier.

60. (Amended) A composition comprising an anti-human CD23 antibody according to claim 54 and a pharmaceutically acceptable carrier. --

Claims 61-70 are new claims:

61. The composition of claim 45, which composition is a pharmaceutical composition.

62. The composition of claim 46, which composition is a pharmaceutical composition.

63. The composition of claim 47, which composition is a pharmaceutical composition.

64. The composition of claim 54, which composition is a pharmaceutical composition.

65. The composition of claim 55, which composition is a pharmaceutical composition.

66. The composition of claim 56, which composition is a pharmaceutical composition.

67. The composition of claim 57, which composition is a pharmaceutical composition.

68. The composition of claim 58, which composition is a pharmaceutical composition.

69. The composition of claim 59, which composition is a pharmaceutical composition.

70. The composition of claim 60, which composition is a pharmaceutical composition. *tv*

REMARKS

This Reply is responsive to the Office Action dated October 22, 2002. Claims 45-47, 49, and 54-60 are amended, and new claims 61-70 are added. Entry of the foregoing amendments and reconsideration and reexamination of the application in light of the remarks that follow are respectfully requested.